Can-Fite Biopharma (CANF) vs Enveric Biosciences (ENVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enveric Biosciences is the larger company by market cap ($6.8 million vs $6.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CANF | ENVB |
|---|---|---|
| Share price | $2.00 | $1.52 |
| Market cap | $6.06M | $6.80M |
| 1-day change | -4.76% | +1.67% |
| YTD return | -50.00% | — |
| 1-year return | -83.05% | — |
| 5-year return | -99.35% | — |
| EPS (TTM) | $-13.23 | $-13.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.40 | $13.25 |
| 52-week low | $1.96 | $1.17 |
| Distance from 52-week high | -83.87% | -88.53% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +300.00% | — |
| Average volume | 388.00K | 102.84K |
| Shares outstanding | 3.03M | 4.48M |
| Employees | 5 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Healthcare · Biotechnology · 5 employees
About Enveric Biosciences
ENVB stock →Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Healthcare · Biotechnology · 5 employees
CANF vs ENVB FAQ
Which is bigger, Can-Fite Biopharma or Enveric Biosciences?
Enveric Biosciences (ENVB) is larger, with a market capitalization of $6.80M compared with $6.06M for Can-Fite Biopharma (CANF).
Are Can-Fite Biopharma and Enveric Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.